

The Board of Directors
Wuhan YZY Biopharma Co., Ltd.
No. 666 Gaoxin Road
East Lake High Tech Development Zone
Wuhan, Hubei Province PRC

30 October 2026

Dear Sirs,

Re: Wuhan YZY Biopharma Co., Ltd. (the “Company”) – Connected Transaction In Respect of the Proposed Issue of New Domestic Shares Under Specific Mandate and Application for Whitewash Waiver

We refer to the circular of the Company dated 30 October 2026 (the “**Circular**”) in connection with the connected transaction in respect of the proposed issue of new domestic shares under specific mandate. Unless otherwise defined, capitalised terms used in this letter have the same meanings as defined in the Circular.

We hereby give our consent and confirm that we have not withdrawn our consent to the issue of the Circular and the inclusion therein of, and all references to, our name, qualification, address and our report, in the form and context in which they respectively appear in the Circular.

We hereby consent to a copy of this letter and our report being made available for display on the websites of the Stock Exchange and the Company as described in the Circular.

[The remainder of this page is intentionally left blank]

Yours faithfully,

For and on behalf of
AVISTA Valuation Advisory Limited

A handwritten signature in black ink, appearing to read 'Vincent', with a stylized flourish extending to the right.

Name: Vincent C B Pang
Title: Managing Partner